Help Us Strike Out Colon Cancer

The 4th annual softball game in memory of Stephen “Diggs” Lisiak took place on Saturday June 4th at Alexander Park in Pierrefonds Quebec under beautiful sunny skies.

Stephen was a great baseball fan and his wife Lisa started the tournament, one year after he lost his battle with colon cancer, to give his family and friends the opportunity to honour and show their love for this great man.

Stephen and Lisa’s son AJ, who was only 17 months when he lost his dad, played in the tournament for the first time. He certainly made his dad proud.

There were activities for all ages including nail painting and tattoos for the kids, multiple raffle prizes and silent auction items, food provided by Dagwood’s and a draw for two Westjet tickets to any of their destinations.

The event raised an incredible $12,475 to be shared by The Colorectal Cancer Association of Canada and Cedars Cansupport.

Get Into The Active Groove: The Colorectal Cancer Association Hosts It’s Third Annual Sortez! Bougez! This June

Physical activity provides many health benefits, such as getting or maintaining a healthy body weight and reducing the risk of colon cancer and many other diseases.

That’s why on Saturday, June 20th, The Colorectal Cancer Association (CCAC), The Dairy Farmers of Canada and U.N.I.Training, have joined forces to host the third Annual Sortez! Bougez!/ Get Out There and Move fitness event to promote the importance of physical activity.

Whether you’re a fitness guru or a beginner looking for a place to kick start your new past time, this event on the Lachine Canal is the place to be. Rain or shine, participants will partake in the CCAC’s endurance, adaptable to all fitness levels.

The challenge, should you choose to accept it, is to take part in four 45 minutes classes showcasing different forms of group training; Zumba, Kickboxing, Boot Camp and Yoga.

This taster pack of physical activity costs participants $30 to register and includes snacks, lunch and beverages throughout the day, which runs from 9:00 AM – 2:00 PM. Any additional sponsorship or doantions will receive a tax receipt. Proceeds will be donated to the CCAC.

“The importance of physical activity cannot be emphasized enough. In today’s society that is moving towards a more sedentary lifestyle, there is a greater need than ever to increase one’s daily activity level to maintain optimal health and prevent future illness. This event is designed to remind people of that and to introduce them to a new way of thinking. We hope to see you there!” Said Barry Stein, CCAC president.

For more information or to join the fitness revolution, visit www.sortezbougez.ca.

Partners in Prevention

The Giant Colon Tour greeted over 1,300 health and safety professionals at the Partners in Prevention 2015 Health and Safety Conference and Trade Show at the International Centre in Mississauga.

It is Canada’s health and safety industry’s largest and longest running conference and trade show, where over 4,000 health and safety professionals connected to do business.

Blue Nose Scotiabank Charity Challenge

Special thanks to the Halifax Fabricville Team, who raised $555 last weekend at the Blue Nose Scotiabank Marathon. Fabricville’s head office will match their $555 for a total of $1110.00 raised for the CCAC. Stay tuned to Facebook for a full list of charity races in your community.

Amazing race guys, Thanks again!

‪#‎fabricville‬ ‪#‎ccac‬

VØID Cancer Makes 1st Donation to CCAC

VOIDI am proud to say that on Sunday, December 28th, I made my first donation on behalf of VØID Cancer (www.voidcancer.com) to The Colorectal Cancer Association of Canada for $948.65 using proceeds collected from the purchase of my Rockstar Mind guitar training products.

The donation will be used to continue to educate and support patients and caregivers much like the CCAC has done for my father and my family.

Without them, I’m not sure where my father would be right now.

So thank you again to everyone who contributed and asked me to help them achieve their dream of playing guitar.

We did it….together!

And in 2015, I plan to raise the stakes, expand the company, and donate even more money to this great cause!

In short, even though I end the year by giving, I am really the one who is left with a feeling of gratitude.

And I think it’s fitting to take a page from my band The Envy and say “I Never Wanna Lose This Feeling”.

With that said, I would like to share an unreleased music video for a track with the same name.

CLICK HERE TO WATCH

Happy New Year and all the best to you and your family in 2015!

Steve (aka VØID)

FDA fast-tracks Taiho Oncology’s TAS-102 for Colorectal Cancer

Otsuka

The US Food and Drug Administration has granted Fast Track designation for TAS-102 (trifluridine and tipiracil hydrochloride), an oral combination anticancer drug under investigation by Taiho Oncology, a unit of Japanese drugmaker Otsuka (TYO: 4768).

The New Drug Application is for the treatment of refractory metastatic colorectal cancer (mCRC), and the company has initiated a rolling NDA submission to the FDA. According to the American Cancer Society, an estimated 136,830 people will be diagnosed with, and 50,310 people will die from, cancer of the colon or rectum during 2014 in the USA.

“We are pleased that TAS-102 has been granted Fast Track designation,” said Fabio Benedetti, senior vice president and chief medical officer at Taiho Oncology, adding: “Patients with metastatic colorectal cancer, whose disease has progressed after treatment with standard therapies, have limited treatment options to manage their disease. We have initiated our rolling NDA submission to the FDA, and are committed to submitting the rest of the filing as efficiently as possible.”

The results from the Phase III RECOURSE trial of TAS-102 in 800 patients affected with mCRC, whose disease had progressed after or who were intolerant to standard therapies, are the foundation for Taiho Oncology’s NDA submission to the FDA.

Taiho Oncology, Otsuka, TAS-102, Fast-track designation, USA, FDA, Colorectal cancer, NDA

 

Calcium, Vitamin D, Dairy Products, and Mortality Among Colorectal Cancer Survivors

Calcium, Vitamin D, Dairy Products, and Mortality Among Colorectal Cancer Survivors: The Cancer Prevention Study-II Nutrition Cohort

Yang B, McCullough ML, Gapstur SM, et al

J Clin Oncol. 2014;32:2335-2343

Study Summary

Diet and lifestyle changes may play an important role in cancer pathogenesis. Yang and fellow American Cancer Society investigators analyzed the role of calcium, vitamin D, and dairy product intake before and after diagnosis of nonmetastatic colorectal cancer. The study population comprised 2284 participants in a prospective cohort study.

In multivariate analysis, post-diagnosis total calcium intake was inversely associated with all-cause mortality (relative risk [RR] for those in the highest relative to the lowest quartiles, 0.72; 95% confidence interval [CI], 0.53-0.98; Ptrend = .02). An inverse association with all-cause mortality was also observed for postdiagnosis milk intake (RR, 0.72; 95% CI, 0.55-0.94; Ptrend = .02), but not for vitamin D intake. Prediagnosis intakes were not associated with mortality.

Viewpoint

Diet and modifiable lifestyle factors are important issues for survivors of localized colorectal cancer. Unfortunately, randomized trials in this setting are difficult to conduct, require prolonged follow-up, and may not be able to control for all lifestyle factors. Therefore, data from well-conducted prospective cohort studies may be good enough to make recommendations to patients.

This study suggests that increased milk and calcium intake is associated with improved outcomes. Limitations include the primarily white study population with known higher rates of lactase persistence; in addition, the lack of association with vitamin D intake is inconsistent with prior reports.[1] Increased milk and calcium intake, along with reduced red meat intake and regular exercise, can be discussion points for survivors of colorectal cancer interested in modifiable lifestyle risk factors.

Abstract

Avec de la viande rouge, mangez des pommes de terre froides

 

Avec de la viande rouge, mangez des pommes de terre froides 

La consommation (excessive) de viande rouge est associée à un risque accru de cancer du côlon. Il s’avère qu’une série d’aliments peuvent atténuer cet effet.

Le premier message, c’est qu’il est important de limiter ses apports en viande rouge : 300 g par semaine, et en tout cas pas plus de 500 g, si possible en choisissant des coupes maigres et en retirant le gras avant la cuisson. Et donc, expliquent ces chercheurs de l’université Flinders (Australie), il est utile d’accompagner sa viande d’aliments riches en fibres (cela on le savait) et en amidon résistant.

Cet amidon présente la particularité de ne pas être (pré)digéré par l’estomac et par l’intestin grêle et dès lors d’arriver intact dans le gros intestin, où il va produire des substances bénéfiques appelées acides gras à chaîne courte. L’équipe australienne a conduit une expérience sur des volontaires adultes et a pu démontrer que l’amidon résistant contrait l’apparition de molécules néfastes liées à la viande rouge.

Comme sources alimentaires, on mentionnera les légumineuses (en particulier les haricots, les pois chiches et les lentilles), les grains entiers (blé, maïs, riz…), les bananes assez vertes, ainsi encore que les pommes de terre cuites et refroidies. Cela ne signifie évidemment pas que la viande rouge peut alors être consommée à volonté, mais que des apports réguliers d’aliments riches en amidon résistant – et en fibres, encore trop négligées ! – peuvent avoir un effet protecteur très intéressant contre le cancer colorectal.

publié le : 21-10-2014

Source: Cancer Prevention Research (http://cancerpreventionresearch.aacrjournals.org)

Boehringer Ingelheim Global Phase III study in patients with Metastatic Colorectal Cancer (mCRC).

Tue, 10/21/2014 – 8:30am

Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed each year. Prognosis is very poor for patients with mCRC with fewer than 10% surviving for more than five years after diagnosis.

LUME-COLON 1 [ClinicalTrials.gov identifier: NCT02149108] is a double-blind, randomized, placebo-controlled study designed to evaluate the safety and efficacy of nintedanib plus best supportive care (BSC), versus placebo plus BSC, after previous treatment with standard chemotherapy and biological agents. This new study will build on previous Phase I/II studies evaluating nintedanib in mCRC.
Nintedanib is an investigational compound in mCRC; its safety and efficacy have not been established.

“Based on previous clinical studies with nintedanib, BI will initiate the LUME-COLON 1 study to evaluate this compound as a potential treatment option for patients with refractory colorectal cancer,” said Berthold Greifenberg, M.D., vice president, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc.

“Patient needs are the driving force behind BI’s innovation in cancer research, and the initiation of this global Phase III study represents our commitment to addressing a critical need in the colorectal cancer community.”

L’analyse de sang, piste d’avenir pour le soin

SOPHIE GUIRAUD

Cancer : l’analyse de sang, piste d’avenir pour le soin 
Marc Ychou et Alain Thierry, partenaires de la start-up DiaDx.

CHRISTOPHE FORTIN

Alain Thierry a mis au point une “biopsie liquide” présentée jeudi au congrès international d’oncologie digestive à Montpellier.

Il y a six mois, il a eu les honneurs de la revue scientifique Nature Medicine : pour la première fois, un chercheur montrait l’intérêt d’une “biopsie liquide”, qui consiste, depuis un échantillon sanguin, à rechercher des mutations génétiques dans l’ADN pour traiter les cancers colorectaux. Depuis, l’idée a fait du chemin. Ce jeudi, Alain Thierry, chercheur Inserm à l’institut de recherche en cancérologie de Montpellier (IRCM), a présenté ses travaux à la conférence internationale d’oncologie digestive organisée jusqu’à samedi au Corum. Le concept est aujourd’hui expérimenté dans une quinzaine de centres en France. Une start-up a été créée. Un développement est envisageable à l’horizon 2016.

Une prise de sang plutôt qu’une biopsie

Explications : “Toutes les cellules relarguent de l’ADN dans le sang, l’ADN circulant”, indique le chercheur. Que se passe-t-il chez un malade ? “Quand une personne a un cancer, l’ADN circulant est relargué en plus grande quantité. C’est un biomarqueur intéressant pour analyser la tumeur. Le test sanguin que nous avons mis au point évite de faire une biopsie pour accéder à des informations capitales dans les choix thérapeutiques à venir. On recherche des mutations génétiques qui, si elles sont présentes, rendent inefficaces un traitement par anticorps”, décrypte Alain Thierry.

Pionnier allemand

L’Allemand Klaus Pantel (CHU de Hambourg), pionnier et expert de l’étude des cellules tumorales circulantes, sera à Montpellier du 14 au 16 octobre 2014 pour une formation de la communauté scientifique et médicale. Il donnera un cours du master international “Cancer Biology” coordonné par le docteur Catherine Panabières, du CHU de Montpellier. Les deux établissements (CHU de Montpellier et de Hambourg) sont associés sur un projet européen de détection des cellules tumorales circulantes dans le cancer de la prostate.

18 000 décès du cancer colorectal par an en France

La méthode a plusieurs avantages : “On gagne du temps, avec un résultat obtenu en 48 h plutôt qu’en un mois. Le test est moins invasif, plus précis, moins coûteux.” L’histoire est loin d’être terminée : “On est dans un programme de recherche clinique”, précise le professeur Marc Ychou, de l’ICM (Institut régional du cancer de Montpellier), associé à Alain Thierry au sein de la start-up DiaDx. Le potentiel est conséquent. Le cancer colorectal touche 40 000 nouveaux patients par an en France, pour 18 000 décès. Enfin, précisent le chercheur et le médecin, “le test est adaptable aux cancers solides comme le sein et le poumon”.